Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury
Y Liu, Y Yang, C Zhang, F Huang, F Wang… - Science China Life …, 2020 - Springer
The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province,
and rapidly spread to many provinces in China as well as other countries. Here we report …
and rapidly spread to many provinces in China as well as other countries. Here we report …
[HTML][HTML] Community transmission of severe acute respiratory syndrome coronavirus 2, Shenzhen, China, 2020
…, F Wang, Y Liu, Z Wang, FS Wang, L Liu… - Emerging infectious …, 2020 - ncbi.nlm.nih.gov
Since early January 2020, after the outbreak of coronavirus infection in Wuhan, China,≈
365 confirmed cases have been reported in Shenzhen, China. The mode of community and …
365 confirmed cases have been reported in Shenzhen, China. The mode of community and …
[HTML][HTML] Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
…, M Li, Z Xu, M Zhang, F Wang, Y Shi, J Yuan, Y Liu - Nature …, 2022 - nature.com
Elucidating the dynamics of the neutralizing antibody (nAb) response in coronavirus disease
2019 (COVID-19) convalescents is crucial in controlling the pandemic and informing …
2019 (COVID-19) convalescents is crucial in controlling the pandemic and informing …
Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019
J Zhao, Q Yuan, H Wang, W Liu, X Liao… - Clinical infectious …, 2020 - academic.oup.com
Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody
response in infected patients remains largely unknown, and the clinical value of antibody …
response in infected patients remains largely unknown, and the clinical value of antibody …
Treatment of 5 critically ill patients with COVID-19 with convalescent plasma
…, F Chen, K Huang, Y Jiang, D Liu, Z Zhang, Y Liu, L Liu - Jama, 2020 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic
agents and substantial mortality. It is critical to find new treatments. Objective To determine …
agents and substantial mortality. It is critical to find new treatments. Objective To determine …
COVID-19: Abnormal liver function tests
…, J Gou, J Qu, Y Sun, Y Liu, Q He, J Chen, L Liu… - Journal of …, 2020 - Elsevier
Background & Aims Recent data on the coronavirus disease 2019 (COVID-19) outbreak
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has begun to …
[HTML][HTML] Experimental treatment with favipiravir for COVID-19: an open-label control study
…, Z Wang, Z Zhang, R Cao, W Zhong, Y Liu, L Liu - Engineering, 2020 - Elsevier
There is currently an outbreak of respiratory disease caused by a novel coronavirus. The virus
has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the …
has been named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the …
Obesity and COVID-19 severity in a designated hospital in Shenzhen, China
…, F Luo, X Liu, Q Wu, Q He, Z Wang, Y Liu, L Liu… - Diabetes …, 2020 - Am Diabetes Assoc
OBJECTIVE Patients with obesity are at increased risk of exacerbations from viral respiratory
infections. However, the association of obesity with the severity of coronavirus disease …
infections. However, the association of obesity with the severity of coronavirus disease …
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
Background The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe
acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and …
acute respiratory syndrome coronavirus 2 was first reported in Wuhan, December 2019, and …
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Neutralizing antibodies could potentially be used as antivirals against the coronavirus disease
2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal …
2019 (COVID-19) pandemic. Here, we report isolation of four human-origin monoclonal …